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Abstract 
 
Glioblastoma (GBM) has a dismal prognosis. Evidence from preclinical tumor models 
and human trials indicates the role of GBM initiating cells (GIC) in GBM drug resistance. 
Here, we propose a new treatment option with tumor enzyme-activatable, combined 
therapeutic and diagnostic (theranostic) nanoparticles, which caused specific toxicity 
against GBM tumor cells and GICs. The theranostic cross-linked iron oxide 
nanoparticles (CLIO) were conjugated to a highly potent vascular disrupting agent (ICT) 
and secured with a matrix-metalloproteinase (MMP-14) cleavable peptide. Treatment 
with CLIO-ICT disrupted tumor vasculature of MMP-14 expressing GBM, induced GIC 
apoptosis and significantly impaired tumor growth. In addition, the iron core of CLIO-ICT 
enabled in vivo drug tracking with MR imaging. Treatment with CLIO-ICT plus 
temozolomide achieved tumor remission and significantly increased survival of human 
GBM bearing mice by more than 2 fold compared to treatment with temozolomide 
alone. Thus, we present a novel therapeutic strategy with significant impact on survival 
and great potential for clinical translation.  
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Introduction 
 
Glioblastoma multiforme (GBM) is the most frequent primary malignant brain tumor in 
adults and the leading cause of cancer-related death in children (1).  The mean survival 
time is 12 months in both adults and children (2). GBM contains GBM-initiating cells 
(GICs) that play a central role in GBM development and disease recurrence (3). GICs 
possess enhanced self-renewal and invasive properties, promote tumor angiogenesis 
and are resistant to the limited number of current therapies, notably temozolomide (4,5). 
Therefore, GICs represent the core problem of the dismal outcome of GBM. To achieve 
improved survival of GBM patients, novel therapeutic strategies are needed that target 
GICs. 
 
GICs are preferentially found in the perivascular niche (6,7) and depend on tumor 
vessels for nutrition supply and survival (8). The efficacy of current GBM therapies with 
oral or intravenous drugs is hindered by their limited trans-endothelial permeability to 
the GIC niche. Previous drug-loaded nanocarrier systems relied on the enhanced 
permeability and retention (EPR) effect in tumors (9,10). However, the highly 
heterogeneous nature of the EPR effect can lead to poor delivery to the GIC niche and 
hence, poor therapeutic efficacy (10). A new, emerging strategy is to deliver vascular-
disrupting agents (VDAs), which do not rely on the EPR effect. VDAs target endothelial 
cells at the intraluminal surface of blood vessels, for example, by disrupting the 
colchicine-binding site of tubulin (11,12). This leads to vascular collapse and starvation 
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of tumor cells supplied by these vessels, a very effective therapeutic strategy (12,13). In 
addition, VDAs selectively destabilize the tumor microvascular endothelial lining, 
causing a transient increase in vascular permeability and drug delivery to the 
perivascular tumor interstitium (14,15), the location of the GIC niche. Thus, the highly 
vascularized nature of GBMs and perivascular location of the GIC-vascular niche have 
spurred a lot of interest in VDAs. Previous VDAs, including combretastatin and 5,6-
dimethylxanthenone-4-acetic acid, have led to significant necrosis in gliomas (16,17).  
However, the clinical efficacy of first generation VDAs was limited by a high prevalence 
of cardiotoxicity (18-20).  
 
To avoid concomitant toxic effects in normal organs, nontoxic VDA-prodrugs can be 
designed, which are activated by specific tumor enzymes (21). For example, matrix 
metalloproteinases (MMPs) and specifically the membrane-type MMPs (MT-MMPs; 
MT1-MMP = MMP-14) subclass represent a ideal target for prodrug activation, because 
they are highly overexpressed in GBM (22-24) and can selectively cleave specific 
peptide sequences (21,25-27). The azademethylcolchicine-peptide conjugate ICT2588 
is metabolized by MMP-14 to release an active VDA, azademethylcolchicine, with 
efficacy against a range of solid tumors (26) and minimal systemic toxicity (28). We 
coupled ICT, a minor structural analogue of ICT2588 (modified to allow conjugation to 
nanoparticles), to cross-linked iron oxide nanoparticles (CLIO) to generate theranostic 
nanoparticles (CLIO-ICT). Initial feasibility studies showed MMP-14-specific cleavage, 
efficient drug delivery and therapeutic efficacy in murine mammary adenocarcinomas 
(29). This new theranostic strategy should be particularly beneficial for GBM, where 
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efficient drug treatment is limited by the blood-brain-barrier and inability to reach the 
perivascular GIC niche. Based on the vascular disrupting properties of the ICT drug 
(26), CLIO-ICT should be able to permeate the tumor microvascular endothelium and 
reach tumor cells and GICs. Thus, we hypothesized that CLIO-ICT will induce 
significant apoptosis of GBM tumor cells and GIC, and thereby, prolong survival of GBM 
bearing mice. 
 
Materials and Methods 
 
Chemicals and Antibodies 
The following antibodies were used: -tubulin (Abcam), CD133 (Miltenyi Biotech), 
CD49F (Biolegend), CD15 (BD Biosciences), CD31 (Abcam), MMP-14 (Abcam), Nestin 
(Abcam) and cleaved caspase-3 (Cell Signaling Technology). The following chemicals 
were used: Ferumoxytol (AMAG Pharmaceuticals), Temozolomide (Sigma), Ilomastat 
(Selleckchem).  
 
Synthesis and characterization of CLIO-ICTs 
ICT and CLIO-ICT were synthesized according to a previously published protocol (29). 
To determine the relaxivities of ferumoxytol and CLIO-ICT, in vitro MRI studies were 
conducted on a 7T MR scanner (Bruker Biospin, Billerica, MA). The transverse 
relaxation times (T2) of ferumoxytol and CLIO-ICT in water with various of Fe 
concentrations (0, 2.5, 5, 10, 20, 40 g/mL) were measured individually using a fast spin 
echo sequence with a repetition time (TR) of ~ 3000 ms, multiple echo times (TE) of 6.8, 
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13.6, 20.4, 27.3, 34 and 40.9 ms. The T2 relaxivity values (r2) was obtained from linear 
least-squares determination of the slope of 1/T2 relaxation rate (s
-1) versus the Fe 
concentration plot. The concentration of iron (Fe) was determined using inductively 
coupled plasma-mass spectrometry (ICP-MS) and the iron (Fe) atoms in each iron 
oxide core was estimated to be ~6200 using Diamond crystal structure analysis 
software. The molar concentration of iron (Fe) in CLIO-ICT stock solution was then 
calculated. Since ICT is linked with FITC, the average amount of ICT covalently 
immobilized to a single CLIO-ICT nanoparticle was determined by the emission intensity 
of FITC. In brief, the emission profile of FITC of a diluted CLIO-ICT solution was 
recorded upon excitation at 495 nm. The concentration of FITC was then estimated 
using a calibration plot obtained from a set of standard FITC solutions. The average 
number of ICT on each CLIO-ICT was then obtained. To determine the sizes of 
ferumoxytol and CLIO-ICT, the samples in DI water at a Fe concentration of 100 g/mL 
were analyzed using a Zetasizer Nano ZS equipment.  
 
Cell Culture 
Two patient-derived GBM cell lines (pcGBM2, pcGBM39) and three commercially 
available GBM cell lines (U87-MG, U138 and A172 from ATCC, Manassas, VA, USA) 
were used for in vitro studies. Both pcGBM2 and pcGBM39 were kindly provided by Dr. 
Sanjiv Sam Gambhir, Stanford University. HCN2, normal cortical neuron cells were 
purchased from ATCC. U87-MG, U138, A172 cells were grown in DMEM (Life 
Technologies) containing 10% FBS and 1% Penicillin/Streptomycin (Life Technologies). 
HCN2 cells were grown in DMEM with 4 mM L-glutamine adjusted to contain 1.5 g/L 
on June 30, 2017. © 2017 American Association for Cancer Research. mct.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on June 28, 2017; DOI: 10.1158/1535-7163.MCT-17-0022 
8 
 
sodium bicarbonate, 4.5 g/L glucose, 90%; fetal bovine serum, 10%. pcGBM2 and 
pcGBM39 were cultured as floating cellular spheres as previously described (30). All 
cell lines used were authentic and confirmed to be mycoplasma negative using the 
MycoAlert Mycoplasma Activity Kit (Lonza). To test for mycoplasma activity, MycoAlert 
substrate was added to the test media (cell supernatant) which catalyzes the conversion 
of ADP to ATP by mycoplasma enzymes in the cell supernatant. This was followed by 
addition of a luciferase reaction mix that cleaved ATP to produce a bioluminescent 
signal as an indication of mycoplasma activity. All cell lines used were from early 
passages.  
Assessment of MMP-14 gene expression of different patient-derived GBM 
neurospheres (pcGBM2 and pcGBM39) and GBM cell lines (U87-MG, U138 and A172) 
as well as human neuronal cortical cells (HCN2) as controls was determined by qPCR 
as previously described (29). qPCR expression analysis for MMP-14 and the control 
marker GAPDH was done and the total cellular RNA was extracted from each sample 
with the QIAGEN RNeasy® mini kit. cDNA was prepared from total RNA and 
quantitative real-time PCRs (qPCRs) were carried out and analyzed on an Applied 
Biosystems StepOne™ Real-Time PCR System. The formation of double-stranded DNA 
product was monitored by TaqMan® gene expression primers. 
 
In vitro evaluation of the therapeutic efficacy of CLIO ICT against GBM cancer 
cells and GIC 
Patient-derived GBM neurospheres (pcGBM2 and pcGBM39) and GBM cell lines (U87-
MG, U138 and A172) as well as human neuronal cortical cells (HCN2) cells were plated 
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in 96 well plates at 2 × 104 cells/well and treated with CLIO-ICT (10 nM), ICT (10 nM), 
CLIO (0.01 mM) and DMSO at 37°C, 5% CO2.  
 
Cell viability after 96 hours was assessed using MTS assay kit (Promega) as per the 
manufacturer’s instruction. At the end of the incubation period, the absorbance was 
measured at 490 nm in a microplate reader (Expert Plus V1.4 ASYS). Cell viability was 
also verified with cell counting following addition of trypan blue (Sigma) at a final 
concentration of 0.1% (v/v), and routine examination of the cells under phase contrast 
microscopy.  
 
For apoptotic assays control and treated pcGBM2, pcGBM39 U87-MG, U138 and A172 
and HCN2 cells were analyzed for caspase-3 activity levels, a marker of cytotoxicity 
using the SensoLyte ® Homogeneous AMC Caspase-3/7 assay kit (AnaSpec, Inc., 
California), according to the manufacturer’s instructions. Release of the AMC 
fluorophore following cleavage of the specific fluorometric caspase substrate, DEVD-
AMC was detected using a fluorometer (ex/em = 354 nm/442 nm). Data were 
normalized relative to the vehicle-treated controls. For flow cytometry-based apoptosis 
detection, control and CLIO-ICT-treated pcGBM39, U87-MG and A172 cells were also 
analyzed by Annexin V-based methods using Annexin V Apoptosis Detection Kit 
(eBioscience, Inc., San Diego, CA). Additionally, control and CLIO-ICT pcGBM39 cells 
were scored for anti-active Caspase-3 (BD Biosciences, San Jose, CA) with 
flowcytometry (BD FACS ARIA II, BD).  
 
on June 30, 2017. © 2017 American Association for Cancer Research. mct.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on June 28, 2017; DOI: 10.1158/1535-7163.MCT-17-0022 
10 
 
For characterization of GICs, pcGBM39 and pcGBM2 were stained for cancer stem cell 
markers using anti-CD133-Biotin (Miltenyi Biotech), CD15-FITC (BD Biosciences) and 
CD49F-PE-Texas red (Biolegend) and analyzed with flow cytometry   
Immunofluorescence staining for -tubulin (Cell Signaling Technology) at 1:25 dilution 
was conducted as previously described.  
 
In vivo evaluation of the therapeutic efficacy of CLIO ICT against GBM cancer 
cells and GIC 
 
In vivo intracranial xenografts 
300,000 cells were injected stereotaxically into the striatum of anesthetized 6 to 8
week old NOD scid gamma (NSG) mice, using the following coordinates: 2 mm 
posterior to the bregma, 2 mm lateral to the midline, and 3–4 mm deep with respect to 
the surface of the skull. Once tumor masses were detected with bioluminescence 
imaging, mice were randomized in four groups and CLIO-ICT, ICT, CLIO or PBS were 
delivered intravenously twice a week for 14 days. Total cumulative doses for each drug 
regimen were: CLIO-ICT (80mg/kg of ICT), ICT (80mg/kg of ICT) and CLIO (0.5 mmol 
Fe/kg).  For combination treatment with temozolomide (33mg/kg), mice were treated 
with ICT and CLIO-ICT twice a week for 21 days. Total cumulative doses for TMZ were 
200 mg/kg respectively.  For determining in vivo tumorigenesis of GICs, 500 
CD133+CD15+, CD133-CD15-, CD49F+CD15+, CD49F+CD15- pcGBM39 cells were 
injected stereotaxically into the striatum of anesthetized 6 to 8 week old NOD scid 
gamma (NSG) mice as described above. Animals were scored for tumor formation with 
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bioluminescence assays until 4 months. All animal maintenance, handling, surveillance, 
and experimentation were performed in accordance with and approval from the Stanford 
University Administrative Panel on Laboratory Animal Care (Protocol 24965). 
 
Bioluminescent imaging 
Luminescent imaging was performed 30 days (for pcGBM39) and 60 days (for pcGBM2) 
after tumor injection on an IVIS Spectrum (Caliper Life Science) and quantified using 
Living Image 4.0 software. D luciferin (firefly) potassium salt solution (Biosynth) was 
prepared (15 mg/ml) and injected intraperitoneally (0.139 g luciferin per kg body 
weight). Total flux (photons per second) values were obtained by imaging mice until 
peak radiance was achieved and quantified with Living Image 4.0 software. 
Bioluminescent imaging was repeated at the end of the treatment and analyzed in a 
blind manner.  
 
Immunocytochemistry 
Mice were euthanized at the end of the treatment for further histological examination. 
For histological analysis, the brains were kept in 10% neutral buffered formalin for 24 h, 
followed by 70% ethanol at room temperature for 24 h. Brains were then embedded in 
paraffin for 3 h at 67°C. Coronal sections (5 μm thick) were stained with hematoxylin 
and eosin, and images were acquired (Eclipse E800, Nikon, USA). Brain tissues were 
also fixed in 4% paraformaldehyde at 4°C overnight and later immersed in 30% sucrose 
for 2 days. Brains were then embedded in OCT and stored in -80°C. Coronal sections 
(5 μm thick) were mounted on superfrost slides, rinsed with phosphate buffered saline 
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(PBS) and permeabilized with 0.1% Triton X-100 made in PBS solution for 15 min. 
Subsequently cells were blocked for 2 hours and stained with primary antibodies 
overnight to determine GIC populations or to evaluate apoptosis upon treatment with 
theranostic nanoparticles. The following dilutions were used: MMP-14 (1:200, Abcam), 
Nestin (1:200, Abcam), cleaved Caspase-3 (1:300, Cell Signaling Technology), CD133 
(1:10, Miltenyi Biotec), and CD15 (1:200, Abcam). Immunofluorescence images were 
acquired with a Leica SP8 confocal microscope using Leica AF software. Images were 
prepared using Adobe Photoshop (Adobe Systems) and analyzed using Velocity 64 
software. 
 
Microvessel density 
Coronal sections (5 μm thick) from PBS, CLIO, ICT and CLIO-ICT treated animals were 
mounted on superfrost slides, rinsed with phosphate buffered saline (PBS), and 
permeabilized with 0.1% Triton X-100 made in PBS solution for 15 min. Subsequently 
cells were blocked for 2 hours and stained with CD31 (1:20, Abcam) antibody overnight 
to determine endothelial cells. Nuclei were counterstained with DAPI and imaged in 
Leica SP5 confocal microscope. Single endothelial cells or clusters of endothelial cells 
positive for CD-31 were considered as a vessel. At first, slides were examined at an 
original magnification of 10×. Three “hot spots“ (areas with the highest microvessel 
concentration) from each slide were identified and these areas were photographed at 
10x. The area of this field was recorded and the number of microvessels in this field will 
be counted with Image-J in a blindfolded manner. MVD (microvessel/mm2) were then 
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assessed according to Weidner et al.,(31). MVD of the specimen were estimated as a 
mean ± SD of MVD in three different fields from three independent experiments. 
 
Flow cytometry  
For detection of apoptosis in GICs and GBM cancer cells, mice were euthanized, and 
brain tumors were dissociated to single cells and stained with anti CD15-APC (BD 
Biosciences) or Annexin V PE (BioLegend) and DAPI. Tumor cells were gated based 
on GFP expression and mouse cells were gated out using a lineage mixture of Brilliant 
Violet 605 conjugated H2kb, H2kd Ter119, and CD45 antibodies. Flow cytometric 
analysis and cell sorting were performed on a BD FACS ARIA II (BD) flowcytometer.  
 
MRI 
We evaluated tumor delivery of CLIO-ICT in GBM-bearing mice using MRI. CLIO-ICT 
comprised of ferumoxytol (CLIO-M) linked to ICT. Ferumoxytol (AMAG 
Pharmaceuticals) comprised of iron oxide nanoparticles that had a mean hydrodynamic 
diameter of 30 nm and provided superparamagnetic signal effects on T1- and T2-
weighted MR images. pcGBM39-bearing mice underwent MRI before and 24 hours after 
intravenous injection of PBS, CLIO, ICT and CLIO-ICT (n=6) and at regular intervals 
during treatments. MRI studies of GBM-bearing mice were performed on a 7T MR 
scanner (Bruker Biospin, Billerica, MA), using a field of view of 2 cm × 2 cm and a slice 
thickness of 0.5mm for the following acquisitions: T2-weighted fast spin echo (FSE): 
repetition time (TR): 4500 ms, echo time (TE): 42 ms, flip angle α: 90° and T2 multi-slice 
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multi-echo (MSME): TR: 3000 ms, TE: 8, 16, 24, 32, 40, 48, 56, 64, 72, 80, 88 and 96 
ms, α: 90°. T2 relaxation times of the tumors were calculated as a quantitative measure 
of tumor contrast enhancement. 
 
Histopathologic correlations of MRI data.  
For Prussian blue iron stains, coronal brain tissue sections (5 μm) of formalin-fixed, 
paraffin-embedded tissue were deparaffinized with xylene, rehydrated, and stained 
according to the manufacturer’s recommendation with the Sigma-Aldrich Accustain Iron 
Stain Kit. Sections were counterstained with nuclear fast red (Fisher Scientific). 
Representative images were captured using the Aperio ScanScope CS Slide Scanner 
with a 20x objective for whole-slide imaging.  
 
Inductively Coupled Plasma Mass Spectrometry (ICP-MS) 
ICP-MS analysis was conducted to study the biodistribution of theranostic CLIO-ICT 
nanoparticles. Briefly, 6‐to 8‐week‐old NOD scid gamma (NSG) mice (n=3) were 
intravenously injected with PBS and CLIO-ICT (80mg/kg of ICT, 0.5 mmol Fe/kg). After 
24 hours, mice were euthanized and different organs including brain, heart, lung, liver, 
kidney and spleen were harvested and processed for ICP-MS (Inductively Coupled 
Plasma Mass Spectrometry) analysis. The tissues were weighed in pre-weighed glass 
tubes and treated with concentrated HNO3 (1g tissue/ml HNO3) and 50 l H2O2. The 
tubes were immersed in oil bath at 110oC overnight to completely digest the samples. 
Samples were considered completely digested when there was no liquid left in tubes. 
The samples were diluted with 5mL of 2% HNO3, gently vortexed and filtered through 
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0.44micron Millipore filter and subjected to ICP-MS analysis. A standard solution of iron 
in the detection range was also included. Amount of iron per sample was obtained and 
expressed as iron per gram of tissue. 
 
Determination of plasma vWF 
We also evaluated the levels of von Willeband Factor (vWF) in plasma from animals 
treated with PBS, ICT and CLIO-ICT. vWF is a marker of cardiotoxicity and was 
detected with kit based ELISA assays (MyBiosource.com) following manufacturer’s 
protocol. Briefly, blood was collected from animals on day 5 after treatment with PBS, 
ICT and CLIO-ICT into heparinized tubes to separate the plasma and stored in -80C. 
The plasma was diluted 1:3 and 100 l of samples or standards were added to murine 
vWF antibody pre-coated plates for 90 min at 37C. The plate was washed with washing 
solution from the kit, followed by incubation with biotinylated vWF antibody for 60 min at 
37C. Then the plate was washed again and enzyme-working solution was added for 30 
min at 37C. After five washes 100 l of color reagent was added for not more than 30 
min. The reaction was then stopped and OD values were measured at 450nm on a 
microplate reader. A known concentration of vWF was used to generate a standard 
curve. The OD of samples was plotted over a standard curve and the concentration of 
plasma vWF was calculated after accounting for dilution factor. Our results indicated 
that CLIO-ICT and ICT did not induce any further increase in plasma vWF levels as 
compared to PBS. However mice administered with doxorubicin showed slightly higher 
levels of vWF and served as our positive control.  
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Statistical analysis 
Cell viability and apoptosis experiments were performed in biological triplicates, in three 
independent experiments. Magnetic resonance, Immunofluorescence, and flow 
cytometry images were representative from three independent experiments. Results 
were presented as mean ± SD unless otherwise presented. Tumor and organ relaxation 
rates and fluorescence signals were compared within multiple experimental groups 
using one-way ANOVA. Results were analyzed using nonparametric two tailed Mann–
Whitney test to compare two groups. Kaplan–Meier survival curves were compared 
using the log rank (Mantel–Cox) test. The level of significance was set at p < 0.05, as 
compared with the control group. Statistical analyses were carried out with Prism 6.0 
software (GraphPad). 
 
Results 
 
Physicochemical properties of CLIO-ICTs 
The concept for MMP-14 activatable theranostic nanoparticles, CLIO-ICTs in GBMs is 
shown in Fig. 1a. ICT and CLIO-ICT were prepared and characterized as previously 
described (29). The hydrodynamic diameter of CLIO-ICT nanoparticles, as measured 
with a Zetasizer Nano ZS analyzer, was 22.10  0.78 nm, slightly larger than 
ferumoxytol nanoparticles (20.27 1.02 nm). The average number of ICT molecules per 
iron oxide nanoparticle was 4.7, based on the attached fluorescein absorption and 
known CLIO-ICT concentration. CLIO-ICTs had higher r2 relaxation rates (276.07 mM
−1 
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s−1) compared to original ferumoxytol nanoparticles (101.18 mM−1 s−1, respectively) (Fig. 
1b). This is likely due to the modified surface coating.  
 
In-vitro anti-tumor effects of CLIO-ICTs in human GBMs  
To evaluate MMP-14 levels, we analyzed the gene expression profile of MMP-14 by 
qPCR in five human GBM cell lines. HCN2, a cell line derived from normal neural cortex 
expressed very low levels of MMP-14 and served as our negative control (Fig. 1c). 
Expression data for MMP-14 was collected as Ct values and the gene expression levels 
were normalized to the reference control gene, GAPDH. While the cell lines U87 and 
U138 expressed increased levels of MMP-14 compared to HCN2 cells (p < 0.005), the 
A172 cell line showed no significant MMP-14 expression (p = 0.103; Fig. 1c). 
Neurospheres were derived from two GBM patients and cultured in neurosphere 
medium (30,32). Compared to HCN2 cells, both pcGBM2 (p = 0.0027; Fig. 1c) and 
pcGBM39 (p = 0.001; Fig. 1c) showed significantly increased MMP-14 expression.  
Next, we investigated the effect of theranostic CLIO-ICT nanoparticles on GBM cell 
viability. In all MMP-14 high GBM cell lines, treatment with both ICT (10 nM) and CLIO-
ICT (10 nM ICT; 0.01 mM CLIO) induced significant (p < 0.005) loss of cell viability 
when compared to CLIO (0.01 mM) or DMSO (Fig. 1d). A172 cells were not responsive 
to treatment and MMP-14 negative normal neural cortex cells (HCN-2) did not show any 
significant cytotoxic effects after incubation with CLIO-ICT or ICT (Fig. 1d). The dose 
range of CLIO-ICT and ICT was chosen based on previous studies (29,33,34) and in 
the case of CLIO, was calculated on the basis of plasma concentrations of CLIO 
reached in patients after clinically applied doses (35-37). In apoptosis assays, GBM 
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cells expressing high MMP-14 showed higher signal for both active caspase-3 
fluorescence and Annexin-V/PI staining after incubation with CLIO-ICT and ICT (Fig. 1e, 
1f and Supplementary Fig. 1a). A172 and HCN2 cells demonstrated minimal induction 
of caspase-3 upon treatment with CLIO-ICT (Fig. 1e). Additionally experiments with 
MMP inhibitor Ilomastat rescued CLIO-ICT toxicity in GBMs, suggesting that activation 
of the CLIO-ICT was MMP-specific (Supplementary Fig. 1b). These results are 
consistent with MMP-14 selectivity shown for CLIO-ICT and ICT2588 as shown in 
previous studies (26,29). 
The apoptotic effects of most VDAs are a result of tubulin disruption in tumor cells and 
tumor endothelial cells. To evaluate if our theranostic nanoparticles retained this 
therapeutic effect, we conducted -tubulin staining in treated and control MMP-14 
expressing GBM cells. Cells treated with both CLIO-ICT and ICT showed dramatic 
alteration in tubulin morphology (Fig. 1g). Control cells showed normal tubulin 
morphology as depicted by spindle shape of the microtubule structures whereas treated 
cells showed retracted tubulin fibers that were aggregated around the nuclear periphery. 
The amount of tubulin was significantly reduced in presence of CLIO-ICT, which was 
quantified as total fluorescence in the red channel. Colchicine-treated cells were used 
as positive controls in these experiments (Supplementary Fig. 1c).   
 
CLIO-ICTs induce apoptosis in GBM initiating cells (GICs) in vitro. 
To study the therapeutic effects of CLIO-ICTs on GICs, we incubated GBM cultures with 
CLIO-ICT (10 nM) and examined GIC apoptosis by Annexin-V/DAPI staining.  
We defined GICs (Supplementary Fig. 2) by a combination of established cell surface 
on June 30, 2017. © 2017 American Association for Cancer Research. mct.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on June 28, 2017; DOI: 10.1158/1535-7163.MCT-17-0022 
19 
 
markers, CD133, CD15 and CD49F (38,39). Considering the heterogeneity of tumors, 
we confirmed the reliability of these markers in identifying GICs in pcGBM39 and 
pcGBM2 (Supplementary Fig. 2), sorting CD133+CD15+, CD133-CD15-, CD49F+CD15+ 
and CD49F+CD15- cells from pcGBM39 and conducting in vivo tumorigenic assay 
(Supplementary Fig. 3). When injected into the right parietal lobe of NSG mice, only the 
CD15+/CD133+ and CD49F+/CD15+ population would generate tumors as early as 8 
weeks, suggesting their tumorigenic potential. This confirmed the GIC like phenotype of 
these cells (Supplementary Fig. 3a, b). 
Next, we investigated whether CLIO-ICTs could induce apoptosis of GICs. pcGBM39 
cells treated with CLIO-ICT demonstrated a significant reduction in the percentage of 
CD133+, CD15+ and CD49F+ populations (p < 0.05; Fig. 1h, 1i). Further, CD133+, 
CD15+ and CD49F+ cells from CLIO-ICT-treated pcGBM39 showed significant 
apoptosis as detected by Annexin-V/DAPI staining (p < 0.005; Fig. 1h, 1i).  
 
Anti-tumor effects of CLIO-ICTs in orthotopic brain tumors initiated from patient-
derived GBM neurospheres. 
Since the VDA activity in tumors is documented (26), we hypothesized that CLIO-ICT 
will target tumor vasculature, GICs and GBM cancer cells (Fig. 2a). To establish an 
orthotopic mouse model for GBM, tumor cells from patient-derived GBM neurospheres, 
pcGBM2 and pcGBM39 were injected into right parietal lobes of NSG mice and tested 
for efficacy of CLIO-ICT (Fig. 2b). The in vivo growth of these GBM neurospheres has 
been previously documented (30,32). MMP-14 expression in these tumors was 
confirmed prior to drug treatment (Supplementary Fig. 4). Both pcGBM2 and pcGBM39 
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were engineered to express firefly-luciferase-GFP and firefly-luciferase expressing 
reporter respectively for in vivo tumor detection with in vivo bioluminescence imaging. 
 
At 3 to 4 weeks post-intracranial cell injection, pcGBM39 tumors were detectable in the 
brain whereas pcGBM2 tumors took longer (8 weeks). Mice were randomized into four 
treatment cohorts: each were i.v injected with CLIO-ICT, ICT, CLIO or PBS twice a 
week for 14 days. Total cumulative doses for each drug regimen were: CLIO-ICT 
(80mg/kg of ICT), ICT (80mg/kg of ICT) and CLIO (0.5 mmol Fe/kg). A longitudinal time 
course study was performed to study the anti-tumor properties of the theranostic 
nanoparticles. Both CLIO-ICT and ICT had significant anti-tumor effects on two different 
GBM types, whereas PBS-treated animals demonstrated increase in tumor size (Fig. 
2c). No tumor response was observed in the CLIO-treated mice, suggesting that the 
therapeutic effect is derived directly from the released VDA entity (Fig. 2c). CLIO-ICT 
significantly inhibited pcGBM39 tumor growth and achieved remission of pcGBM2 
tumors (Fig. 2c, 2d, p < 0.005). PBS or CLIO-treated animals drastically lost body 
weight over time, while CLIO-ICT and ICT-treated sets demonstrated no significant 
weight loss (p > 0.05; Supplementary Fig. 5). CLIO-ICT improved survival by 100%, 
200% and 220% compared to ICT, CLIO or PBS-treated mice (p < 0.05; Fig. 2e). 
Pathologic evaluation confirmed decreased tumor size and increased tumor apoptosis 
following CLIO-ICT treatment compared to CLIO or PBS-treatment (Fig. 3a, 3b). We 
also investigated the biodistribution of CLIO-ICT in tumor free NSG mice using 
Inductively Coupled Plasma Mass Spectrophotometry (ICP-MS).  Results show that 
CLIO-ICT was accumulated in lungs, liver, spleen and kidney (Supplementary Fig. 6a, p 
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< 0.05). Brain and heart showed very little CLIO-ICT (Supplementary Fig. 6a, p > 0.05). 
Next we measured CLIO-ICT toxicity in normal organs (brain, heart, lung, liver, spleen 
and kidney) by evaluating the amount of apoptotic marker, caspase-3. 
Immunofluorescence data showed negligible expression of active caspase-3 in these 
organs from CLIO-ICT-treated animals when compared to PBS-treated group 
(Supplementary Fig. 6b). Since previous VDAs are known to induce cardiotoxicity, we 
further confirmed that CLIO-ICT is minimally cardiotoxic. In addition to caspase-3 
staining, we also measured plasma vWF levels in both PBS and CLIO-ICT-treated 
animals. vWF is conventionally used as a marker for cardiotoxicity (28). Our data show 
that no significant difference was observed for plasma vWF levels in PBS and CLIO-ICT 
treated animals. In summary CLIO-ICT was found to be non-toxic to normal organs 
(Supplementary Fig. 6c).   
 
To further compare tumor retention of macromolecular CLIO-ICT and small molecular 
ICT, we measured drug quantities of FITC-labeled ICT and CLIO-ICT in pcGBM39 
tumor specimen with immunofluorescence assays. CLIO-ICT treated tumors 
demonstrated significantly higher FITC intensity as compared to ICT only (p < 0.05), 
suggesting improved tumor retention of ICT when linked to a nanocarrier (Fig. 3b).  
To better understand the tumor retention of CLIO-ICT in vivo, we next imaged 
pcGBM39-bearing mice on a 7.0 T small animal MRI system. We found that GBM 
showed a signal drop or negative (hypointense) enhancement on T2-weighted MR 
images after intravenous injection of CLIO and CLIO-ICT, while PBS or ICT-
administered mice showed little or no loss in tumor signal (Fig. 3c, 3d). When 
on June 30, 2017. © 2017 American Association for Cancer Research. mct.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on June 28, 2017; DOI: 10.1158/1535-7163.MCT-17-0022 
22 
 
comparing pre-and post-injection images in each group, we found that tumor T2 
relaxation times decreased significantly after CLIO and CLIO-ICT injection (p < 0.005) 
and did not change significantly after ICT or PBS injection (Fig. 3c, 3d). When 
comparing different treatment groups, tumor T2 relaxation times of CLIO and CLIO-ICT-
treated tumors were significantly shorter compared to the ICT only and PBS groups (p < 
0.05). This was consistent with histopathological evaluations: Prussian blue staining 
demonstrated iron deposits within CLIO and CLIO-ICT-treated groups, but not PBS or 
ICT-treated groups (Fig. 3a).  
 
Next, longitudinal MR scans were obtained on week 1 and 2 for each group to non-
invasively monitor therapy response in tumors. For each time point, tumor volume was 
calculated and plotted against time. CLIO-ICT was most effective in inhibiting tumor 
growth (Fig. 3e). In addition, the degree of tumor T2 signal enhancement, quantified as 
tumor T2 relaxation time, correlated with tumor volume (Spearman rank correlation, 
r=0.7; p<0.001). Thus, CLIO-ICTs could be used for noninvasive monitoring of drug 
delivery and therapy response in orthotopic GBM models using MRI. 
 
To understand the therapeutic mechanism, we evaluated the effect of CLIO-ICT on 
tumor vasculature and GICs. We used CD31 as a marker for GBM endothelial cells 
(7,40). Both CLIO-ICT and ICT treatment significantly inhibited microvessel density in 
pcGBM39 tumors (p < 0.05; Fig. 4). In addition, CLIO-ICT significantly reduced the GICs 
in pcGBM39–bearing mice, as demonstrated by reduced staining for CD133, CD15 and 
Nestin (p < 0.005; Fig. 4,) and significantly increased staining for Annexin-V/Dapi (p < 
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0.05; Fig. 5). We confirmed this observation using flow cytometry and firefly-luciferase-
GFP expressing pcGBM2 cells. We observed that CLIO-ICTs triggers GBM cell 
apoptosis in vivo, as GBM cells (GFP-positive) from CLIO-ICT-treated mice presented 
higher levels of Annexin-V and DAPI staining compared to glioblastoma cells from 
vehicle-treated mice (Fig. 5a, 5b). Of note, CLIO-ICT did not induce apoptosis in non-
tumor stromal (GFP-negative) cells (Fig. 5b, 5c), further confirming the absence of 
toxicity of this drug on normal cells.  The percentage of CD15+ GICs was significantly 
reduced in presence of CLIO-ICTs whereas apoptosis staining in CD15+ GICs from 
CLIO-ICT-treated mice was significantly increased (p < 0.05; Fig. 5b, 5d). 
 
The above results suggest that the therapeutic efficacy of CLIO-ICT is due to disruption 
of tumor vasculature and GIC apoptosis. 
 
CLIO-ICTs in combination with temozolomide impedes tumor growth and 
improves survival in GBM-bearing animals. 
Next, we assessed whether CLIO-ICT could be used in combination with standard 
clinical anti-GBM treatment, such as temozolomide (TMZ). Before proceeding to in vivo 
studies, a panel of GBM cells was screened in vitro for TMZ sensitivity with MTS-based 
viability assays, which demonstrated varying profiles of TMZ toxicity (Fig. 6a). For our in 
vivo studies, we proceeded with TMZ responsive pcGBM39 and pcGBM2 cells to test if 
CLIO-ICT would add therapeutic benefit. At three and eight weeks post-intracranial 
injection, pcGBM39 and pcGBM2-bearing mice were randomized into treatment groups: 
TMZ (200 mg/kg; cumulative dose) was orally administered either alone or in 
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combination with ICT/CLIO-ICT (80mg/kg; cumulative dose), twice per week for three 
consecutive weeks. At 3 weeks after initiation of treatment, MRI scans revealed 7 fold 
reduction in tumor size for TMZ plus CLIO-ICT-treated pcGBM39-bearing mice relative 
to that of vehicle-treated mice, which showed 30 fold increase in tumor size after 
treatment (Fig. 6b, 6c). The combination of TMZ plus CLIO-ICT significantly inhibited 
pcGBM39 tumor growth (p < 0.005), induced complete remission of pcGBM2 tumors 
and increased overall survival as compared to TMZ plus ICT and single drug regimens 
(Fig. 6d-i).  
 
Discussion 
Data showed that novel MMP-14-activatable cross-linked iron oxide nanoparticles 
(CLIO-ICT), which where conjugated with the VDA ICT (a structural analogue of 
ICT2588), caused significant apoptosis of cancer cells and GIC in GBM. This led to 
significantly prolonged survival of pcGBM39 bearing mice and complete tumor 
remission of pcGBM2 bearing mice. CLIO-ICT synergized with temozolomide in vivo, 
thereby revealing a novel therapeutic combinatorial regimen for targeting GBMs.  
Current GBM therapies include surgical resection followed by radiation therapy with 
concurrent temozolomide (TMZ) treatment (41).  However 90% of GBM patients 
develop tumor recurrence (42). This is partly attributed to poor drug delivery and drug 
resistant GIC (43). Nearly all large molecules and the majority of small molecular drugs 
including tyrosine kinase inhibitors are effluxed at the blood brain barrier by P-gp and 
Bcrp on the luminal side of endothelial cells, and never reach therapeutic levels in the 
brain (44). Another major challenge involves the multiple molecular pathways of GBMs. 
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Identifying just one therapeutic target is insufficient, as this does not account for the 
considerable array of genetic and epigenetic heterogeneities found within and among 
GBM patients (45). Our approach addresses most of these challenges: CLIO-ICT does 
not rely solely on a passive delivery across the tumor microvessel wall via the EPR 
effect (9,10). The VDA rather increases vascular permeability through active disruption 
of the tumor microvessel endothelial lining. This effect is specific to tumor vessels 
through tumor enzyme activation (28), and efficacious in tumors with different molecular 
codes. Both ICT-mediated vessel disruption and nanoparticle-mediated enhanced 
permeability and retention (EPR) support accumulation of CLIO-ICT in the tumor 
interstitium. CLIO-ICT causes tumor blood vessel collapse, cancer cell starvation and 
jeopardizes the tumor microenvironment, making this a very effective therapeutic 
strategy (26). We further demonstrate for the first time that CLIO-ICT is capable of 
inducing apoptosis in GBM initiating cells (GICs).  
 
Agemy et al. reported that theranostic nanoparticles linked to a tumor vasculature 
homing peptide (CGKRK) showed exceptional efficacy in eliminating a lentivirus-
induced GBM model. However, this drug could not completely inhibit the growth of 
orthotopically transplanted GBM (46). By contrast, our CLIO-ICT achieved almost 
complete remission of orthotopic pcGBM2 tumors and significantly inhibited pcGBM39 
tumors, both of which express MMP-14. Literature shows that MMP-14 expression is 
positively correlated with tumor grade and disease progression of gliomas (23,47). 
Therefore our MMP-14 targeted approach seems specifically suited for the treatment of 
high grade GBMs.  
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Since our theranostic nanoparticles are based on two clinically applicable components, 
the combined CLIO-ICT has high potential for clinical translation: CLIO-ICT is 
composed of the FDA-approved nanoparticle compound ferumoxytol, linked to a VDA 
based on ICT2588. ICT2588 is on course to be evaluated in a phase I clinical trial in the 
UK for treatment of advanced tumors outside of the CNS in 2017. Further since CLIO-
ICT are activated by tumor MMP-14 to release the potent VDA specifically in tumor 
tissue, potential side effects of cardiotoxicity, as noted with previous VDAs, are 
minimized (28).   
 
VDA-based strategies sensitize GBMs to chemotherapy through three mechanisms: (1) 
VDAs jeopardize the perivascular GIC niche, which provides access to vascular 
nutritions but shields GIC from classical chemotherapy agents, such as TMZ.  (2) VDAs 
disrupt tumor-promoting vascular endothelial cells. Borovski et al., found that tumor 
microvascular endothelial cells (tMVECs) isolated from human GBM tumors promoted 
the proliferation of human CD133+ cells when GIC-tMVEC co-cultures were exposed to 
irradiation and TMZ (48,49). By contrast, CLIO-ICT had inhibited both tumor endothelial 
cells and GIC, thereby eliminating endothelial cell-mediated GIC rescue. (3) CLIO-ICT is 
activated by tumor-specific enzymes, i.e. the activation is “built-in” and does not rely on 
external stimuli. By contrast, previous generations of theranostic nanoparticles had to 
be activated by near-infrared phototherapy (50). These approaches are more difficult to 
translate to the clinic and were accompanied with severe side effects, such as severe 
cerebral edema (50).  
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In summary CLIO-ICT holds signiﬁcant clinical potential for improving targeted therapy 
and survival in GBM patients. Significant advantages of CLIO-ICT compared to other 
theranostic agents include selective and effective delivery to GBM, therapeutic efficacy 
independent of EPR effect, prolonged retention in the tumor tissue via VDA initiated 
vascular collapse, drug entrapment in the GIC niche, ability to track the drug with MRI 
and eliminated toxicity-liability to normal organs. Further our approach of combining 
CLIO-ICT with TMZ offers refinements to current less optimal standards of care in order 
to achieve GBM remission.  
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Figures and Legends 
 
Figure 1. CLIO-ICTs inhibit GBM and GIC survival in vitro. (a) Schematic 
demonstration of CLIO-ICT activation in presence of tumor enzyme MMP-14, to release 
the active drug, azademethylcolchicine. Azademethylcolchicine targets tubulin to induce 
apoptosis in tumor cells. (b) Representative T2 weighted MR images of CLIO-ICT and 
ferumoxytol at different dilutions. T2 MSME sequences were used to generate R2 
relaxivites. R2 relaxivities of CLIO-ICT (blue line) and ferumoxytol (red line). (c) 
Graphical representation of MMP-14 expression in different GBM cells lines. MMP-14 
expression was measured with q-PCR assay, GAPDH served as endogenous control. 
(d) Viability analysis of GBMs treated with CLIO-ICT (10nM), ICT (10nM), CLIO 
(0.01mM) and PBS. GBMs were treated for 96 hrs and viability was assayed using MTS 
assay. (e) Graph shows fold change for cleaved caspase-3 in control and treated GBM 
cells. Cleaved caspase-3 fluorescence signals were detected by SensoLyte 
Homogeneous AMC Caspase-3/7 assay kit and the fold change was represented by the 
ratio: fluorescence signals in treated/fluorescence signals in control. (f) Annexin-V/PI 
apoptosis staining in control and treated GBM39 cells (Left panel). Right panel depicts 
quantification for percentage apoptosis in A172, U87 and pcGBM39 cells after 48 hrs of 
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treatment.  (g) Immunofluorescence for -tubulin in control and treated U87 cells. Upper 
panel shows confocal images and lower panel depicts quantification of tubulin signals 
scale bar 10m. (h) Flow cytometry analysis of GIC markers (CD133, CD15 and 
CD49F), Annexin V/DAPI staining in control and treated pcGBM39 cells. CLIO-ICT-
treated pcGBM39 were subjected to flow cytometric staining for GIC surface markers 
(upper panel) and apoptosis markers (lower panel). (i) Graph shows percentages of 
CD133+, CD15+ and CD49F+ GICs (left) and percentage apoptosis (right) in gated 
CD133+, CD15+ and CD49F+ GICs from control and treated pcGBM39 cells. Results are 
represented as mean ± SD from three independent experiments. *P < 0.05, **P < 0.005, 
one-way ANOVA. 
 
Figure 2. CLIO-ICTs retard GBM growth in vivo.  (a) Schematic demonstration of 
CLIO-ICT-mediated anti-GBM effect. In presence of tumor enzyme MMP-14, CLIO-ICT 
is cleaved to release the active vasculature-disrupting agent, azademethylcolchicine. 
Activated CLIO-ICT targets tumor vasculature and induces apoptosis in GICs and 
GBMs, thereby inhibiting GBM growth and improving survival outcomes. (b) Schematic 
representation of experimental design. Tumors were initiated with orthotopic injections 
of primary human GBM samples (pcGBM39 cells and pcGBM2 cells that express 
luciferase and GFP-luciferase construct respectively) into the striatum of NSG mice. 
Treatment was initiated once the tumors were detected and bioluminescent analyses 
were performed during and after treatment. (c) Bioluminescent in vivo images of tumors 
in mice treated with CLIO-ICT (0.5 mmol Fe/kg and 80mg/kg of ICT), ICT (80mg/kg of 
ICT), CLIO (0.5 mmol Fe/kg) or vehicle. (d) Quantification of the bioluminescent signals. 
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Fold change in total flux represents the ratio: total flux after treatment/total flux before 
treatment. *P = 0.0002 and *P = 0.0003 for pcGBM39 (n=8) and pcGBM2 (n=6), 
respectively, one-way ANOVA. (e) Kaplan–Meyer survival curves of control and treated 
mice demonstrate a significant survival benefit of CLIO-ICT as compared to vehicle, log-
rank Mantel–Cox test.  
 
Figure 3. CLIO-ICTs are delivered to GBM tumors and induce tumor apoptosis. 
Tumors were initiated with orthotopic injections of pcGBM39 tumors and mice were 
treated with CLIO-ICT (0.5 mmol Fe/kg and 80mg/kg of ICT), ICT (80mg/kg of ICT), 
CLIO (0.5 mmol Fe/kg) or vehicle. (a) Upper panel: Representative H&E staining for 
brain coronal sections from control and treated animals. White arrows indicate tumor. 
Objective 4X. Scale bar represents 100 m. Middle panel: Prussian blue iron staining 
for control and treated tumors. Objective 4X. Scale bar represent 100m. Lower panel: 
Prussian blue at higher magnification 10x for boxed regions in middle panel. Scale bar 
represent 40 m (b) Representative immunofluorescence confocal images for cleaved 
caspase-3 in control and treated pcGBM39 tumors. Arrows indicate cleaved caspase-3 
positive cells. Nuclei counterstained with DAPI. Scale bar represents 75 m. Graph 
shows quantification for FITC and cleaved caspase-3 staining in control and treated 
pcGBM39 tumors. Results are represented as mean ± SD from three independent 
experiments. *P < 0.05, **P < 0.005, one-way ANOVA. (c) Representative T2 weighted 
MR images of mice brain. T2 FSE sequences were used to capture coronal T2 weighted 
images. Nanoparticle and theranostic nanoparticle delivery is demonstrated by T2 
darkening or negative enhancement in CLIO and CLIO-ICT treated animals 
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respectively. On day 14 tumor periphery is marked by dotted yellow line. (d) 
Quantification of T2 darkening. T2 MSME sequences were used to generate T2 maps, 
Osirix software was used to calculate T2 values. CLIO and CLIO-ICT-treated tumors 
demonstrated shorter T2 values corresponding to T2 darkening or negative 
enhancement. (e) Quantification of tumor volumes before and after treatment. T2 
weighted MR scans were used to calculate tumor volumes using Osirix software. 
*P < 0.05, **P < 0.005, n=6, one-way ANOVA.  
 
Figure 4. CLIO-ICTs target GBM vasculature and GICs in vivo. Tumors were 
established with orthotopic injections of pcGBM39 cells. Mice were treated with CLIO-
ICT (0.5 mmol Fe/kg and 80mg/kg of ICT), ICT (80mg/kg of ICT), CLIO (0.5 mmol 
Fe/kg) or vehicle. Representative immunofluorescent confocal images depicting CD31, 
CD133, CD15 and Nestin staining in pcGBM39 tumors. CD31 is used to outline tumor 
vasculature. CD133, CD15 and nestin are used to mark GICs. Signal intensity for CD31, 
CD133, CD15 and nestin in control and treated tumors have been quantified and 
represented graphically. Scale bar represent 20 m (CD31) and 10 m (CD133, CD15 
and nestin). Results are representative of three independent experiments. *P < 0.05, 
**P < 0.005, one-way ANOVA. 
 
Figure 5. CLIO-ICTs induce GIC apoptosis in vivo. Tumors were initiated with 
orthotopic injections of pcGBM2 cells. Mice were treated with CLIO-ICT (0.5 mmol 
Fe/kg and 80mg/kg of ICT), ICT (80mg/kg of ICT), CLIO (0.5 mmol Fe/kg) or vehicle. 
Flow cytometric analysis of GIC markers (CD15), Annexin V and DAPI in (a) vehicle and 
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(b) CLIO-ICT-treated pcGBM2 tumors. GFP positive pcGBM2 tumors were gated and 
analyzed for percentage apoptosis in both (c) pcGBM2 cells and (d) GICs from 
pcGBM2. P < 0.05, **P < 0.005, n=6, one-way ANOVA.  
 
Figure 6. CLIO-ICTs increase the anti-tumor efficacy of temozolomide (TMZ) in 
vivo. (a) In vitro analysis of TMZ chemosensitivity by cell viability assay. Panel of GBM 
cells were exposed to increasing doses of TMZ (0-500 M) for 72hrs and cell viability 
was calculated by MTS assay. For in vivo experiments, tumors were initiated with 
orthotopic injections of pcGBM39 cells (b-f) and pcGBM2 cells (g-i). Mice were treated 
with TMZ alone (200mg/kg) or in combination with CLIO-ICT (0.5 mmol Fe/kg and 
80mg/kg of ICT) and ICT (80mg/kg of ICT), CLIO (0.5 mmol Fe/kg) or vehicle. (b) 
Representative T2 weighted MR images of mice brain. T2 FSE sequences were used to 
capture coronal T2 weighted images. Yellow dotted line represents tumor periphery. (c) 
Quantification of tumor volumes before and after treatment. T2 weighted MR scans were 
used to calculate tumor volumes using Osirix software. Bioluminescent in vivo images of 
tumors in control and treated mice in pcGBM39 (d) and pcGBM2 (g) tumor models. (e 
and h) Quantification of the bioluminescent signals. Fold change in total flux represents 
the ratio: total flux after treatment/total flux before treatment. *P < 0.05, 
respectively, n = 6 (pcGBM39) and n = 6 (pcGBM2), one-way ANOVA. (f and i) 
Kaplan–Meyer survival curves of control and treated mice (n=6, pcGBM39; n=6, 
pcGBM2) demonstrate a significant survival benefit of CLIO-ICT and ICT in combination 
with TMZ as compared to vehicle, log-rank Mantel–Cox test. *P < 0.05, **P < 0.005, 
n=6, one-way ANOVA.  
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